Who is sponsoring NCT02281227?

NCT02281227 is sponsored by Yonsei University.

What drugs are being tested in NCT02281227?

Interventions in NCT02281227: skin compression.

What condition does NCT02281227 study?

NCT02281227 studies Low Back Pain Due to Spinal Nerve Compression.

Is NCT02281227 still recruiting?

NCT02281227 is currently completed. Last updated 22 February 2019.

Last reviewed 2019-02-22 · How we verify

NCT02281227

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determination of a Proper Needle Entry Point; Effects of Skin Compression With an Indicator on Radiation Exposure Time of Fluoroscopically Guided Transforaminal Epidural Block in Obese Patients

Completed NA Last updated 22 February 2019

What this trial tests

NA trial testing skin compression in Low Back Pain Due to Spinal Nerve Compression in 60 participants. Completed in 10 October 2015.

Timeline

20 October 2014

Primary endpoint
10 October 2015

10 October 2015

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	60
Start date	20 October 2014
Primary completion	10 October 2015
Estimated completion	10 October 2015
Sites	1 location across South Korea

Drugs / interventions tested

skin compression

Conditions studied

Low Back Pain Due to Spinal Nerve Compression — all drugs for Low Back Pain Due to Spinal Nerve Compression →

Sponsor

Yonsei University

Who can join

Adults 20 to 80, any sex, with Low Back Pain Due to Spinal Nerve Compression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effects of skin compression with an indicator at the needle entry point on radiation exposure time of fluoroscopically guided transforaminal epidural block in obese patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02281227 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 22 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02281227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing